← VERA: big moves and long-term fundamentals中文

Vera Therapeutics: The Long View

What the filings say about its story, dilution and cash runway.

Last updated Nov 11, 2026 · Reflects: 10-K FY2025, the 10-Q for Q3 2026 and the Q3 release and call (Nov 5, 2026)

Disclosure: one or more of our editors own shares of Vera Therapeutics (VERA) as a long-term investment. This page is information, not investment advice.

Sources used most:

1. In one paragraph

Last updated Nov 11, 2026. Reflects the 10-K FY2025, the 10-Q for Q3 2026 and the Q3 release and call (Nov 5, 2026).

Vera is a biotechnology company with one approved product, Trutakna. It began selling it in July 2026 and booked $10.3M of net product revenue in Q3 2026, its first sales. It lost $93.7M in Q3, so its spending is still funded by the money it has raised and borrowed. It reports one operating segment (10-Q).

  • Product: Trutakna (atacicept) is a once-weekly injection that patients give themselves at home with an autoinjector. It blocks BAFF and APRIL, two signalling proteins that drive the B cells (antibody-producing white blood cells) behind IgA nephropathy (IgAN), an immune disease that damages the kidneys.
  • Approval: the FDA granted Trutakna accelerated approval (approval based on an early marker, with continued approval subject to confirmatory data) on Jul 7, 2026, to reduce proteinuria (protein in the urine) in adults with primary IgAN at risk of disease progression (8-K, Jul 7). Vera submitted its application for full approval (a supplemental Biologics License Application, or sBLA) on Nov 3, 2026 (Q3 release).
  • Revenue: $10.3M of net product revenue in Q3 2026, sold through specialty pharmacies and specialty distributors. About 700 patient start forms (prescription requests) had been received since launch, as of Nov 5; Vera has not disclosed how many patients are on paid therapy (Q3 release; 10-Q, note 2). About half of Q3 sales were patient demand and about half inventory, the chief commercial officer said (reported, Q3 call).
  • Costs: in 2025 it recorded $315.5M of operating expenses, made up of research and development $215.3M (68%) and general and administrative $100.2M (32%) (our calculation)1; interest and other income brought the net loss to $299.6M (10-K). In Q3 2026: cost of sales $3.3M, research and development $41.3M, and selling, general and administrative $61.4M; net loss $93.7M (Q3 release).
  • Licence: Vera licensed atacicept from Ares Trading, an affiliate of Merck KGaA, and owes Ares milestones and tiered royalties of “low double-digit to mid-teen” percentages on net sales (10-Q, note 5).
  • Market: Vera says about 160,000 people in the US are diagnosed with IgAN, about 75% of them commercially insured (Q3 release).

2. Story so far

Last updated Nov 11, 2026. Reflects filings and releases through Nov 5, 2026.

In short: Vera listed in 2021 with atacicept, a drug it licensed from Merck KGaA’s affiliate Ares, and funded two positive mid- and late-stage trials in IgAN through five share sales and a loan. The FDA approved the drug, as Trutakna, on its target date in July 2026, and two-year kidney-function results followed in September, two quarters earlier than Vera had guided in May. First sales of $10.3M came in Q3, and Vera filed for full approval in November. It sells Trutakna against a rival from Otsuka, with Vertex’s similar drug due for an FDA decision on Nov 30, 2026.

Date Milestone Source
Oct 2020 Licenses atacicept from Ares for 22.2M Series C preferred shares (converted into 1.91M Class A shares at the initial public offering, or IPO), plus milestones and royalties 10-K FY2022, licence note
May 14, 2021 Class A shares start trading on Nasdaq after the IPO 10-K FY2025, Item 5
Jan 2023 ★ ORIGIN Phase 2b (a mid-stage trial) meets its primary endpoint, a cut in proteinuria at 24 weeks; Vera then sells 16.4M shares at $7.00 in February 10-K FY2022; prospectus
Oct 26, 2024 Phase 2b data show kidney function (eGFR, a measure of how well the kidneys filter blood) held stable through 96 weeks; Vera sells 7.14M shares at $42.00 in October and another 1.07M in November after the underwriters exercised their option Release; prospectus
Jun 2, 2025 ★ ORIGIN 3 (the Phase 3 trial) meets its primary endpoint: proteinuria −46% from baseline and −42% versus placebo at 36 weeks Release (8-K)
Jun 2, 2025 Signs a loan agreement with Oxford Finance for up to $500M; $75M funded on Jun 4, 2025, refinancing the earlier $50M loan 8-K, Jun 3, 2025; 10-Q, note 6
Aug 5, 2025 Opens a $200M at-the-market (ATM) share-sale programme with TD Cowen; no sales had been made by Sep 30, 2026 8-K; 10-Q
Nov 2025 Submits the Biologics License Application (BLA) for accelerated approval; on Jan 7, 2026 the FDA grants priority review with a Jul 7, 2026 target date 10-K FY2025, Item 1
Dec 2025 Sells 7.06M shares at $42.50, raising $300.0M gross Prospectus; 10-K FY2025
Jun 2, 2026 Agrees with the FDA on an earlier final ORIGIN 3 kidney-function analysis, now expected in Q3 2026 (the May 7 guide was Q1 2027) 8-K; Q1 release
Jul 7, 2026 ★ FDA grants Trutakna accelerated approval in IgAN; Vera pays Ares a $20.0M milestone in August 8-K; 10-Q, note 5
Sep 15, 2026 ★ ORIGIN 3 final analysis (428 patients): eGFR slope −0.6 vs −5.6 mL/min/1.73m² a year on placebo through 104 weeks; 76% lower risk of kidney-disease progression events (hazard ratio 0.24, meaning the estimated rate of such events was 24% of placebo’s); more than 350 patient start forms (prescription requests) in the first ten weeks of launch Release (8-K)
Oct 22, 2026 Full ORIGIN 3 results presented at the American Society of Nephrology (ASN) Kidney Week and published in the New England Journal of Medicine; supplemental BLA (sBLA) for full approval planned for Q4 2026 Release
Oct 28, 2026 Our coverage starts with this Long View —
Nov 5, 2026 Q3 results: first sales of $10.3M; about 700 start forms; full-approval filing (sBLA) made Nov 3; $75M loan tranche drawn in October Q3 release

3. Latest quarter: did the story change?

Last updated Nov 11, 2026. Reflects Q3 2026 (quarter to Sep 30, 2026), the release, 10-Q and call (Nov 5, 2026).

Bottom line: First sales of $10.3M and about 700 start forms; the full-approval filing is in; Sep 30 cash was $384.0M ($459M pro forma, adjusting only for the $75M October borrowing), with about $99M of operating cash use in the quarter; Vertex’s rival drug has an FDA date of Nov 30.

Driver Last quarter → this quarter Management: before → now Signal
Net product sales None → $10.3M “Limited revenue” expected in Q3 (Aug 10) → launch “building early momentum”; about half of Q3 sales were demand and half inventory, with the demand share expected to go “much higher” (reported) Better
Patient start forms (cumulative) More than 350 (Sep 15) → about 700 (Nov 5) Patients on paid therapy not disclosed; forms to be reported by quarter, with revenue to become the primary indicator (reported) Better
Full approval sBLA planned for Q4 → filed Nov 3 Approval “2027” → “mid-2027”, subject to FDA review; EU filing in Q1 2027 Better
Operating cash use Q2 $100.3M → Q3 $99.2M (our calculation)2 For context: G&A/SG&A $52.4M → $61.4M; R&D $60.1M → $41.3M, partly because manufacturing costs now go into inventory Unchanged
Cash and loan $499.2M → $384.0M $75M tranche drawn in October (principal now $150M); $50M drawable through year-end; up to $350M remains, subject to conditions Watch

Sources: Q2 2026 release, Q3 2026 release, 10-Q Q2 2026, 10-Q Q3 2026, 8-K, Sep 15, release, Oct 22. Statements from the earnings call are reported, from a third-party transcript (Q3 call).

Unresolved questions: how many start forms become patients on paid drug; the discount from list price, which Vera has not disclosed; and how Vertex’s label and price compare.

4. Buybacks vs real dilution (5 years)

Last updated Nov 11, 2026. Reflects the equity statements in the 10-K FY2022, 10-K FY2025 and 10-Q Q3 2026.

Dilution in one line: shares outstanding (Class A plus Class B) rose 239.7% from Dec 31, 2021 to Sep 30, 2026, about 29.4% a year compounded (our calculation)3. If you owned 1% of Vera at the end of 2021, you’d own about 0.294% on Sep 30, 2026 without buying more (our calculation)4. Buybacks offset about 0.01% of the new shares (our calculation)5. Our scale: High (over 3% a year).

Our rule of thumb: under 1% a year low, 1–3% moderate, over 3% high.

Change in shares outstanding, Dec 31, 2021 to Sep 30, 2026FY2022 +30.6%, FY2023 +59.9%, FY2024 +43.0%, FY2025 +12.1%, 9M 2026 +1.4%. Total +239.7% since Dec 31, 2021.0%+50%+100%+150%+200%+250%FY2022: +30.6% in the period; +30.6% since Dec 31, 2021+30.6%FY2022FY2023: +59.9% in the period; +108.9% since Dec 31, 2021+59.9%FY2023FY2024: +43.0% in the period; +198.7% since Dec 31, 2021+43.0%FY2024FY2025: +12.1% in the period; +234.9% since Dec 31, 2021+12.1%FY20259M 2026 (part year): +1.4% in the period; +239.7% since Dec 31, 2021+1.4%9M 2026+239.7%since Dec 31, 2021

Change in the period Total since Dec 31, 2021 Part year

Shares outstanding at period end (all classes): 21.3M on Dec 31, 2021, 72.3M on Sep 30, 2026, +239.7% (our calculation). A bar below zero means the count fell (net buybacks).

All common shares, Class A plus non-voting Class B (which converted into Class A in 2022), from the author's bridge (10-K and 10-Q equity statements).

Period endShares outstandingChangeBuybacks (fiscal year)Stock-based pay (fiscal year)Stock pay as % of revenue
9M 2026 (Sep 30, 2026)72.3M+1.4%———
FY2025 (Dec 31, 2025)71.3M+12.1%$0$38M—
FY2024 (Dec 31, 2024)63.6M+43.0%$0.0M$21M—
FY2023 (Dec 31, 2023)44.5M+59.9%$0$11M—
FY2022 (Dec 31, 2022)27.8M+30.6%—$9M—
FY2021 (Dec 31, 2021)21.3M——$3M—

Shares outstanding from the balance sheets in the company's 10-K and 10-Q filings; buybacks (cash spent) and stock-based pay from its 10-Ks, via SEC EDGAR.

Vera has made no buyback programme purchases. Nearly all new shares came from five underwritten share sales between 2022 and 2025; employee plans added the rest.

How we calculated this

Share basis:

  • The headline and the bridge count all common shares, Class A plus non-voting Class B.
  • The Dec 31, 2021 count is 20,968,376 Class A plus 309,238 non-voting Class B shares; the Class B shares converted into Class A in 2022, and none are outstanding now (10-K FY2022, equity statement).
  • There are no pre-funded warrants. Vera’s 11.5869-for-one reverse split took effect on May 7, 2021, before it listed; all counts here are after it, and there has been no split since (10-K FY2022, note 1).
Bridge (millions of shares) 2022 2023 2024 2025 Nine months 2026 Total
Start of period 21.28 27.80 44.45 63.56 71.27 21.28
Share sales for cash (underwritten offerings) 5.74 16.43 17.49 7.06 – 46.72
Stock pay and employee plans (options, restricted stock units, share purchase plan) 0.50 0.22 1.62 0.65 1.02 4.01
Shares issued for a licence (Novartis, MAU868) 0.28 – – – – 0.28
Acquisitions or convertible notes 0 0 0 0 0 0
Buybacks 0 0 −0.004 0 0 −0.004
End of period 27.80 44.45 63.56 71.27 72.29 72.29
  • Totals use unrounded filing figures (10-K FY2022, 10-K FY2025 and 10-Q equity statements). In Q3 2026 there was no share offering and no at-the-market sale; employee plans added 332,019 shares.
  • The 2022 licence shares (283,034) went to Novartis in exchange for a $7.0M reduction in future MAU868 development milestones.
  • The 2024 buyback line is a 4,450-share repurchase for $13K shown in the equity statement; the filing does not describe it as a buyback programme.

Prices paid and received:

Period Shares bought back Average price paid Spent Shares sold for cash Average price received Raised Sources
2022 — — — 5.74M $15.00 $86.1M (our calculation)6 Prospectus, Feb 2022; 10-K FY2022
2023 — — — 16.43M $7.00 $115.0M Prospectus, Feb 2023; 10-K FY2025, cash flow statement
2024 4,450 shares $2.92 (our calculation)7 $13K 17.49M $36.17 (our calculation)8 $632.5M 10-K FY2025: 9.27M shares issued in February at $31.00 ($287.5M; January prospectus) and 8.21M issued in October–November at $42.00 ($345.0M, including the underwriters’ option; October prospectus)
2025 — — — 7.06M $42.50 $300.0M Prospectus, Dec 2025; 10-K FY2025
2026 to date (Jan 1–Sep 30) — — — — — — 10-Q Q3 2026: no sales under the ATM programme
  • Prices are per share; Vera has not split its stock since listing in May 2021.
  • Raised is gross proceeds before underwriting fees and costs; derived averages are our calculation (see the notes). Employee option exercises and share-purchase-plan sales are excluded.
  • No share sale after Sep 30, 2026 had been disclosed by Nov 11; the share count was 72,298,770 on Oct 29, 2026 (10-Q, cover).
  • For reference, Yahoo Finance reports (not independently verified) a closing price of $30.48 on Nov 11, 2026 (historical prices).
Stock-based pay 2022 2023 2024 2025 Nine months 2026
$M 8.9 11.5 20.8 37.9 44.8
% of operating expenses (our calculation)9 (Vera had no revenue before Q3 2026) 10% 11% 12% 12% 13%

Stock-based pay was about 436% of revenue in the first nine months of 2026, the first period with sales (our calculation)9.

At Sep 30, 2026, 9.73M options (average exercise price $24.52) and 2.25M unvested restricted stock units (awards that deliver shares when vesting conditions are met) were outstanding (10-Q, note 8). Together they equal about 16.6% of the 72.29M shares outstanding (our calculation)10.

5. Profit vs cash (latest FY and TTM)

Last updated Nov 11, 2026. Reflects the 10-K FY2025 and the 10-Q Q3 2026, including the nine-month 2025 comparative figures it presents. Vera reports no adjusted profit measure.

Vera’s cash outflow was smaller than its net loss in both periods; stock-based pay is the main non-cash cost, and licence milestones are paid through investing cash flow.

$M FY2025 Trailing twelve months (TTM) to Sep 30, 2026 (our calculation)11
Net loss −299.6 −415.3
Adjusted metric Not reported Not reported
Operating cash flow −241.1 −375.9
Capital spending (property and equipment, plus internal-use software in 2026) −0.6 −0.8
Free cash flow (our calculation)12 −241.7 −376.7

The 12 months to Sep 30, 2026 include only one quarter of sales ($10.3M), so the snapshot’s price-to-sales and enterprise-value-to-sales ratios rest on the first quarter of sales alone. Enterprise value (EV) is market value plus debt minus cash and investments.

Sorted by what each reconciling item does next:

Helps future profit or cash:

  • Launch working capital: in the first nine months of 2026, receivables used $12.0M, inventory $7.1M, and prepaid expenses and other assets $24.4M of operating cash (10-Q, cash flow statement). Receivables come back as cash when customers pay; inventory and prepaid costs are already paid, so they reach the income statement later without another cash payment.
  • Pre-launch inventory: about $29.1M of manufacturing costs was expensed in R&D before approval, and about $26.0M of that inventory remained at Sep 30, 2026. Had those costs been capitalised, Q3 cost of sales would have been about $0.4M higher. Vera says early cost of sales may not be indicative of the full cost of units sold (10-Q, note 3).
  • Interest income accrued on discounted securities ($7.0M in 2025): counted in the loss now, with the cash arriving at maturity.

Hurts future profit or cash:

  • Stock-based pay ($37.9M in 2025; $55.8M TTM; our calculation)13: a recurring cost that lowers reported profit; it is added back as a non-cash expense and shows up as new shares (dilution) instead.
  • Payables and accrued liabilities (+$13.9M and +$14.4M in 2025): cash kept for now that goes out when the bills are paid.
  • Ares milestones still to come: $10.0M is due on the first EU filing, which Vera expects in Q1 2027 (10-Q, note 5; Q3 release).
  • An October 2026 cancellation of some scheduled R&D manufacturing, with an estimated loss of up to $14.6M that Vera expects to record in Q4 2026 R&D; the filing doesn’t say how much is new cash or when (10-Q, note 9).

One-off / no lasting effect:

  • Licence milestones already paid: the $15.0M Ares BLA-filing milestone in Q1 2026 (expensed in R&D), the $20.0M Ares approval milestone paid in August 2026 (capitalised and amortised through cost of sales), and a $0.8M VT-109 licence fee in 2025. All are paid through investing cash flow, so operating cash flow does not show them.
The raw reconciling items
  • Stock-based pay added back $37.9M in 2025 ($55.8M TTM; our calculation)13.
  • Licence milestones are paid through investing cash flow ($35.0M in the first nine months of 2026); the $15.0M BLA-filing milestone was expensed in R&D and added back in operating cash flow (10-Q, 10-K cash flow statements).
  • Working capital provided cash in 2025: payables rose $13.9M and accrued liabilities $14.4M. In the first nine months of 2026, receivables used $12.0M, inventory $7.1M and prepaid expenses and other assets $24.4M ($24.8M TTM; our calculation)13; payables used $1.7M and accrued liabilities provided $3.6M (10-Q).
  • Interest income accrued on discounted securities ($7.0M in 2025; $3.0M in the first nine months of 2026) is counted in the loss before the cash arrives at maturity.

Funding: how long without new money? At the past rate and with known items, cash would fall below zero in Q4 2027 (cash path below): cash, cash equivalents and marketable securities of $384.0M at Sep 30, 2026 covered about 1.0 year, or about 4.1 quarters, of TTM free cash outflow of $376.7M (our calculation)14. Vera drew a further $75M of its Oxford loan in October (net cash of $74.0M); no debt principal is due within 24 months, and a further $50M is drawable by Dec 31, 2026.

Funding details
  • In October 2026, Vera drew the $75M Oxford tranche made available by approval and received $74.0M net of fees and prepaid interest; principal is now $150M. Pro forma for that borrowing alone, Sep 30 cash, equivalents and marketable securities would have been $459M (10-Q, note 6; Q3 release).
  • Subject to the loan’s conditions, Vera may draw a separate $50M by Dec 31, 2026.
  • Vera’s own statements: its Sep 30 cash, equivalents and marketable securities, together with amounts available under its loan agreement, will fund planned operations and capital spending for at least the next 12 months from the 10-Q date (MD&A). Note 1 makes the 12-month assessment on Sep 30 cash and securities alone (10-Q).
  • Debt: $75.0M of Oxford term loans at Sep 30, 2026, interest-only until August 2029; for that amount, principal is due $34.1M in 2029 and $40.9M in 2030, with maturity in June 2030 (extended to June 2031 if Vera meets a revenue-based milestone). The 10-Q gives no schedule for the October tranche. A final fee of 5% of principal is due at maturity or prepayment. No convertible notes (10-Q, note 6).
  • This is based on past cash flow; spending plans can change it.

Financing items, sorted by what they do to the runway. Vera can draw up to $350M more under the Oxford agreement, subject to conditions (Q3 release):

Oxford loan capacity of up to $500M, by status
DrawnDraw by Dec 31, 2026Two milestone tranchesMutual discretionOxford loanOxford loan, Drawn: $150MOxford loan, Draw by Dec 31, 2026: $50MOxford loan, Two milestone tranches: $100MOxford loan, Mutual discretion: $200M$500M
Show the data
Label Drawn Draw by Dec 31, 2026 Two milestone tranches Mutual discretion Unit
Oxford loan 150 50 100 200 $M

Chart source15.

Extends the runway:

  • $50M Oxford tranche, at Vera’s discretion until Dec 31, 2026 (not shown as drawn in the filings we reviewed; see the table below the cash path).
  • The $75M October draw is in the cash path below, as a known item in Q4 2026.

Shortens the runway:

  • Oxford principal: $34.1M due in 2029 and $40.9M in 2030 on the $75M outstanding at Sep 30 (maturity June 2030), plus the final fee of 5% of principal; the October tranche adds $75M of principal, with no schedule in the 10-Q.
  • Loan covenants: from Mar 31, 2027, a minimum-cash covenant applies unless Vera’s market value is at least $1.0B; once more than $200M of loans is funded, a loan-coverage test replaces it unless market value is at least $1.25B (10-Q, note 6).
  • Minimum manufacturing purchases of $88.1M ($38.9M in the rest of 2026; $49.2M in 2027), and the October manufacturing cancellation, with an estimated loss of up to $14.6M (10-Q, note 9).

Conditional:

  • Two Oxford tranches of up to $50M each, available only on commercial milestones for Trutakna.
  • Up to $200M of the Oxford loan at the mutual discretion of Vera and Oxford (uncommitted).
  • ATM programme: $200M with TD Cowen (August 2025), all of it unused at Sep 30, 2026 (10-Q). Uncommitted: it adds cash only if Vera chooses to sell shares.

Cash path (our calculation; an illustration, not a forecast):

At the past rate and with known items, cash would fall below zero in Q4 2027.

Illustration, not a forecast.

Cash path: ending cash by quarter (illustration)Start $384M, Q4 2026 $364M, Q1 2027 $270M, Q2 2027 $176M, Q3 2027 $81M, Q4 2027 −$13M.Q4 2026: raising window (under a year of usual spending left)Q1 2027: raising window (under a year of usual spending left)Q2 2027: raising window (under a year of usual spending left)Q3 2027: raising window (under a year of usual spending left)Q4 2027: would need new money−$100M$0M$100M$200M$300M$400M$500MIf the committed financing is drawn: Oxford loan: existing tranche $50M (Q4 2026)Q4 2027, if drawn: $37M2Start: $384MQ4 2026: $364MQ1 2027: $270MQ2 2027: $176MQ3 2027: $81MQ4 2027: −$13MStartQ4 2026Q1 2027Q2 2027Q3 2027Q4 2027Q4 2026: known item $74M (Net proceeds of the $75M Oxford tranche drawn in October (10-Q, note 6). Less than a year of usual spending left.)1
  1. 1 · Q4 2026 · Net proceeds of the $75M Oxford tranche drawn +$74M
  2. 2 · Cash if drawn: $37M at Q4 2027

Ending cash (cash, equivalents and marketable securities) Known item Raising window (under a year of usual spending left) Would need new money If committed financing is drawn

Quarter Starting cash Usual spending Known items Ending cash Sources / notes
Q4 2026 +384.0 −94.2 +74.0 +363.9 Net proceeds of the $75M Oxford tranche drawn in October (10-Q, note 6). Less than a year of usual spending left.
Q1 2027 +363.9 −94.2 0.0 +269.7 Less than a year of usual spending left.
Q2 2027 +269.7 −94.2 0.0 +175.5 Less than a year of usual spending left.
Q3 2027 +175.5 −94.2 0.0 +81.3 Less than a year of usual spending left.
Q4 2027 +81.3 −94.2 0.0 −12.9

Amounts in $M.

Usual spending is an even quarter’s share of the past year’s free cash flow, about −$94.2M a quarter, held flat (our calculation)16.

Financing that could extend the runway (committed but undrawn; not in the path above; the chart draws it as a dashed “if drawn” line):

Quarter Financing that could extend the runway Amount Conditions Source
Q4 2026 Oxford loan: existing tranche $50M At Vera’s discretion; must be drawn by Dec 31, 2026; subject to the loan’s conditions 10-Q Q3 2026, note 6

If drawn, the $50M would cover about half a quarter more of usual spending (our calculation)15. Drawn money carries interest (the greater of the 1-month SOFR or 3.75%, plus 4.95%) and a final fee of 5% of principal, which the path does not include.

At the past rate and with known items, cash would fall below zero in Q4 2027. Vera says its Sep 30 cash, equivalents and marketable securities, together with amounts available under its loan agreement, cover planned operations and capital spending for at least the next 12 months (MD&A); Note 1 makes the 12-month assessment on Sep 30 cash and securities alone (10-Q). Our path assumes flat spending at the past rate: it includes customer receipts only as far as they are in the past 12 months’ cash flow, assumes no further growth in sales receipts, and leaves out the added interest on the October loan. Companies usually raise money well before that; quarters with less than a year of usual spending left are shaded.

Known items:

  • Q4 2026: $74.0M net proceeds of the $75M Oxford tranche drawn in October (10-Q, note 6).
  • No other disclosed, dated debt maturities, acquisition payments or completed raises before the path turns negative; Oxford principal falls due only in 2029–30. The $20.0M Ares approval milestone was paid in August, before the Sep 30 starting cash.
How we calculated this
  • Usual spending is TTM free cash flow (−$376.7M, Q4 2025–Q3 2026) ÷ 4 ≈ −$94.2M a quarter (our calculation)16, held flat.
  • Calculations use unrounded amounts (starting cash $384.042M, quarterly spending −$94.180M); displayed values are rounded to $0.1M.
  • Starting cash is cash, cash equivalents and marketable securities at Sep 30, 2026.

Not included:

  • Oxford principal ($34.1M in 2029 and $40.9M in 2030 on the Sep 30 balance, plus the October tranche), which falls after the quarter in which the path turns negative, and the added interest on the October loan.
  • Ares milestones: $10.0M on the first EU filing, which Vera expects in Q1 2027 (cash date not disclosed); up to $131.5M of other regulatory milestones; and up to $515.0M of sales milestones, starting with $15.0M when annual net sales reach $250M (10-Q, note 5).
  • The estimated loss of up to $14.6M on the October manufacturing cancellation, which Vera expects to record in Q4 2026 R&D; the filing doesn’t say how much is new cash or when (10-Q, note 9).
  • The undrawn $50M tranche and the unused ATM programme, which are not completed raises (the committed tranche is in the financing table above).
  • Any growth in customer cash receipts beyond the past 12 months: sales began only in Q3 2026.
  • Lease payments and ordinary manufacturing, trial and launch costs, which are already in past free cash flow (future minimum lease payments were $3.0M at Dec 31, 2025; 10-K). Capital spending is small ($0.8M TTM, $0.6M in 2025) and Vera has disclosed no capital-spending plan.

6. Customer and contract exposure

Last updated Nov 11, 2026. Reflects the 10-K FY2025, the 10-Q Q3 2026 and the Q3 release and call (Nov 5, 2026).

Vera began selling Trutakna in Q3 2026 through specialty pharmacies and specialty distributors. Two customers accounted for 76% and 18% of Q3 gross product revenue, and for the same shares of gross receivables at Sep 30, 2026 (10-Q, note 2). Its other main exposures are its licences, its lender, its contract manufacturers and payers.

The licence from Ares carries $10.0M on the first EU filing and up to $131.5M of other regulatory and $515.0M of sales milestones, plus royalties on sales. Vera paid the $20.0M approval milestone in August 2026 and capitalised it, amortised through cost of sales; royalties now also run through cost of sales. The Oxford loan is the only debt.

Ares milestone payments for atacicept: paid, due and possible
Paid in 2020: $25MPaid in 2020$25MPaid on BLA filing (Jan 2026): $15MPaid on BLA filing (Jan 2026)$15MPaid on approval (Aug 2026): $20MPaid on approval (Aug 2026)$20MDue on first EU filing: $10MDue on first EU filing$10MOther regulatory milestones (up to): $132MOther regulatory milestones (…$132MSales milestones (up to): $515MSales milestones (up to)$515M
Show the data
Label Value Unit
Paid in 2020 25.0 $M
Paid on BLA filing (Jan 2026) 15.0 $M
Paid on approval (Aug 2026) 20.0 $M
Due on first EU filing 10.0 $M
Other regulatory milestones (up to) 131.5 $M
Sales milestones (up to) 515.0 $M

Chart source17. Milestones are paid in cash on the stated events; royalties are on top.

Contract terms
Contract Signed Terms Source
Ares (Merck KGaA affiliate) licence: atacicept Oct 2020 Worldwide rights. Paid $25.0M in 2020, $15.0M on the BLA filing (Jan 2026) and $20.0M on approval (paid Aug 2026); $10.0M on the first EU filing; up to $131.5M of other regulatory milestones and up to $515.0M of sales milestones ($15.0M at $250M of annual net sales, $50.0M at $500M). Tiered royalties of “low double-digit to mid-teen” percentages, payable quarterly, country by country until the latest of 15 years after first sale, the last valid patent claim, or regulatory exclusivity 10-Q, note 5; 10-K
Stanford licence: VT-109 (preclinical) Jan 2025 Global rights; upfront fee ($0.8M paid in 2025), annual maintenance fees, milestones and royalties, plus a share of any sublicensing income 10-K
Novartis licence: MAU868 (BK virus antibody) Dec 2021; amended Sep 2022 Vera issued 283,034 shares in 2022 to cut future development milestones by $7.0M. Remaining contingent milestones: up to $62.0M to Novartis and up to $7.0M to Amplyx (a Pfizer subsidiary), plus mid- to high-single-digit percentage royalties to Novartis. The licence runs to the end of the royalty term; Vera may terminate it for convenience on 60 days’ written notice 10-K FY2022; 10-K
Oxford Finance loan Jun 2, 2025 Up to $500M; $75.0M drawn at Sep 30, 2026 and a further $75M in October ($150M); floating rate of the greater of the 1-month term Secured Overnight Financing Rate (SOFR, a benchmark interest rate) or 3.75%, plus 4.95%; secured by substantially all assets except intellectual property, which is subject to a negative pledge (Vera has agreed not to pledge it to other lenders, subject to exceptions in the agreement); limits mergers and a change in control 10-Q, note 6; 8-K
Manufacturing agreements (two suppliers) Not disclosed Minimum purchase obligations of $88.1M within 18- and 16-month periods ($38.9M in the rest of 2026; $49.2M in 2027). In October 2026 Vera cancelled some scheduled R&D manufacturing, with an estimated loss of up to $14.6M, to be recorded in Q4 2026 R&D 10-Q, note 9
TD Cowen sales agreement (ATM) Aug 5, 2025 Up to $200M of shares; commission up to 3.0%; unused at Sep 30, 2026 10-Q; 8-K

Commercially insured patients are about 75% of diagnosed US IgAN patients, Trutakna’s US exclusivity runs to Jul 7, 2038, Otsuka’s rival Voyxact is on sale, and Vertex’s rival drug has an FDA decision due Nov 30, 2026.

Payers, exclusivity, competition and other items
  • Payers: Vera says about 75% of diagnosed US IgAN patients are commercially insured, and eligible commercially insured patients may pay as little as $0 through its support programme (Q3 release). Vera is on track for a goal of 50% of covered lives by year-end; it did not give current coverage (reported, Q3 call).
  • Exclusivity: as a biologic, Trutakna has 12 years of US market exclusivity from approval, to Jul 7, 2038 (our calculation)18 (10-K); that bars biosimilar copies relying on Trutakna’s data, not independently developed drugs. The licensed issued patents (purification, formulation, methods of treatment) are expected to expire between 2027 and 2029, before any extension; patents from pending IgAN-treatment applications would expire in 2041 (10-K, Item 1). Vera has orphan designation in the EU and Japan and said in the 10-K that it was seeking one in the US.
  • Competition: Otsuka’s Voyxact (sibeprenlimab), which blocks APRIL, received FDA accelerated approval in IgAN on Nov 25, 2025 (Otsuka). Vertex’s povetacicept, which also blocks BAFF and APRIL, has an FDA target action date of Nov 30, 2026 for accelerated approval in IgAN (Vertex Q2 release).
  • Cost of sales: about $29.1M of pre-launch manufacturing was expensed in R&D before approval; about $26.0M of that inventory remained at Sep 30, 2026, so early cost of sales is low and, Vera says, may not be indicative of the full cost of units sold (10-Q, note 3).
  • Legal: Vera believes no pending action would have a material adverse effect on its financial statements (10-Q, note 9).

7. Vera’s strategy for long-term growth

Last updated Nov 11, 2026. Reflects the 10-K FY2025, the 10-Q for Q3 2026 and the Q3 release and call (Nov 5, 2026).

Vera is building on one drug: first full approval and Europe for Trutakna in IgAN, then atacicept in other antibody-driven kidney diseases; so far it has reported its first quarter of sales and no sales targets.

  • Pressures on the core business: Trutakna is Vera’s only product, and its approval is accelerated, so continued approval depends on confirmatory data. Otsuka’s Voyxact is already on sale in IgAN, and Vertex’s povetacicept, which blocks the same two targets, has an FDA decision due Nov 30, 2026. Trutakna’s US biologic exclusivity runs to Jul 7, 2038 (our calculation)18; the licensed issued patents expire between 2027 and 2029, before any extension (10-K).
  • The strategy in management’s words: Trutakna’s “potential to become a foundational therapy in IgAN” (CEO Marshall Fordyce, Q3 release). The steps so far:
    • full approval: the sBLA was submitted on Nov 3, 2026, with potential full approval in adults with primary IgAN expected in mid-2027, subject to FDA review (Q3 release);
    • Europe: a Netherlands-based subsidiary was formed in September 2026 (10-Q, note 2), and the application for standard EU marketing authorisation is planned for Q1 2027 (Q3 release);
    • other kidney diseases: the Phase 2 PIONEER trial tests atacicept in broader IgAN populations and in primary membranous nephropathy, focal segmental glomerulosclerosis and minimal change disease; interim results were presented at ASN Kidney Week, and Vera expects additional results in Q4 2026 (10-Q);
    • monthly dosing: a dose-range study is testing once-monthly atacicept; analysis of the new-patient cohorts is due this quarter and of a weekly-to-monthly switch cohort in Q2 2027, and Vera will review the results internally first (reported, Q3 call);
    • earlier programmes: MAU868 (BK virus antibody, licensed from Novartis) and VT-109 (preclinical, licensed from Stanford) (10-K).
  • How well it is working, in numbers:
    • $10.3M of net product revenue in Q3 2026, the first quarter of sales; about half of it was demand and about half inventory (reported, Q3 call);
    • about 700 patient start forms since launch, as of Nov 5 (Q3 release);
    • ORIGIN 3 two-year results, as Vera reports them: eGFR slope of −0.6 mL/min/1.73m² a year, against −5.6 on placebo, and a 76% lower risk of kidney-disease progression events (Q3 release);
    • targets: Vera has not given sales or profit targets.
  • What to watch: see section 8.

8. What to watch

Last updated Nov 11, 2026. Reflects the 10-Q Q3 2026 and the Q3 release and call (Nov 5, 2026).

Date Item Source
Nov 30, 2026 FDA target action date for Vertex’s povetacicept in IgAN Vertex Q2 release
Dec 31, 2026 Deadline to draw a further $50M Oxford tranche 10-Q Q3 2026, note 6
Q4 2026 “Additional” PIONEER results 10-Q Q3 2026
Year-end 2026 Goal of 50% of covered lives for Trutakna Q3 call (reported)
Q1 2027 Application to the European Medicines Agency for standard marketing authorisation; $10.0M Ares milestone due on the first EU filing Q3 release; 10-Q Q3 2026, note 5
Mar 31, 2027 Oxford minimum-cash covenant starts, unless Vera’s market value is at least $1.0B 10-Q Q3 2026, note 6
Mid-2027 Potential full approval of Trutakna in adults with primary IgAN, subject to FDA review of the sBLA Q3 release
Additional dates
Date Item Source
Q4 2026 Analysis of the once-monthly dosing cohorts Q3 call (reported)
Q2 2027 Results of the weekly-to-monthly switch cohort Q3 call (reported)

Valuation at each update

At the close used for each update, from the filings available then. Frozen when the update is published; never revised.

UpdateCloseMarket valueEVP/SEV/salesP/EP/FCFRevenue growthFCF marginNet cash (debt)Basis
Oct 28, 2026$27.99 (Oct 23)$2.0B$1.6Bn/mn/mn/mn/mn/mn/m$424M12 months to Jun 30, 2026; pre-revenue
Nov 11, 2026$30.48 (Nov 11)$2.2B$1.9B214.4×184.4×n/mn/mn/m−3666%$309M12 months to Sep 30, 2026

Our calculation from each update's filings (latest at the newest update: 10-Q for the quarter to Sep 30, 2026, filed Nov 5, 2026); not investment advice. n/m = not meaningful (e.g. negative earnings). Hover a heading for its definition. Oct 28, 2026 price: the Long View's stated close (Yahoo Finance). Nov 11, 2026 price: official close, Yahoo Finance, CNBC.

Notes and calculations

  1. Shares of 2025 operating expenses: R&D $215.256M ÷ $315.473M = 68.2%; G&A $100.217M ÷ $315.473M = 31.8%. ↩

  2. Q3 2026 operating cash use = nine months 2026 $305.929M − H1 2026 $206.753M = $99.176M. Q2 2026 = H1 2026 $206.753M − Q1 2026 $106.500M = $100.253M. ↩

  3. Total change = 72,287,904 ÷ 21,277,614 − 1 = 239.7%. Annual rate = (72,287,904 ÷ 21,277,614)^(1 ÷ 4.75) − 1 = 29.4%, where 4.75 years = Dec 31, 2021 to Sep 30, 2026. The start count is 20,968,376 Class A plus 309,238 Class B shares. ↩

  4. 1% × 21,277,614 ÷ 72,287,904 = 0.294%. ↩

  5. New shares issued = 72,287,904 − 21,277,614 + 4,450 repurchased = 51,014,740; 4,450 ÷ 51,014,740 = 0.0087%, about 0.01%. ↩

  6. Gross proceeds = 5,742,026 shares × $15.00 = $86.1M. ↩

  7. $13K ÷ 4,450 shares = $2.92 a share. ↩

  8. $632.5M gross ÷ 17,488,480 shares = $36.17. Components: 9,274,194 × $31.00 = $287.5M; 8,214,286 × $42.00 = $345.0M. ↩

  9. Stock-based pay ÷ total operating expenses: $8.887M ÷ $90.903M (2022), $11.493M ÷ $102.012M (2023), $20.802M ÷ $167.170M (2024), $37.926M ÷ $315.473M (2025), $44.799M ÷ $343.601M (nine months 2026; total operating expenses include $3.296M of cost of sales). Against revenue: $44.799M ÷ $10.277M = 435.9%. ↩ ↩2

  10. (9,726,290 options + 2,245,765 unvested RSUs) ÷ 72,287,904 shares = 16.6%. ↩

  11. TTM = FY2025 − nine months 2025 + nine months 2026. Net loss: −$299.615M − (−$208.518M) + (−$324.216M) = −$415.313M. Operating cash flow: −$241.104M − (−$171.110M) + (−$305.929M) = −$375.923M. Capital spending: −$0.630M − (−$0.528M) + (−$0.023M − $0.673M) = −$0.798M. ↩

  12. Free cash flow = operating cash flow + capital spending (a negative number): FY2025 −$241.104M − $0.630M = −$241.734M; TTM −$375.923M − $0.798M = −$376.721M. ↩

  13. TTM items = FY2025 − nine months 2025 + nine months 2026. Stock-based pay: $37.926M − $26.961M + $44.799M = $55.764M. Prepaid expenses and other assets: −$3.928M − (−$3.506M) + (−$24.353M) = −$24.775M. ↩ ↩2 ↩3

  14. Cash, cash equivalents and marketable securities = $384.042M at Sep 30, 2026 (cash and cash equivalents $55.322M). Runway = $384.042M ÷ $376.721M = 1.02 years (4.1 quarters). ↩

  15. Chart source: 10-Q, note 6; Q3 release. Drawn: $75M at closing in June 2025 plus $75M in October 2026 = $150M. Remaining: $50M by Dec 31, 2026 + two milestone tranches “each of a maximum of $50.0 million” ($100M together) + $200M at mutual discretion = $350M; $150M + $350M = $500M. If drawn, $50M ÷ $94.180M a quarter ≈ 0.5 quarters of usual spending. Interest and fees on drawn money would add to spending. ↩ ↩2

  16. −$376.721M ÷ 4 = −$94.180M a quarter. ↩ ↩2

  17. Chart source: 10-Q, note 5. ↩

  18. Jul 7, 2026 approval + 12 years of US biologic exclusivity = Jul 7, 2038. ↩ ↩2

Quoting this? You may quote short excerpts under our reuse policy. Please credit WhyMyStockMoved.com and link to this page.

About Vera Therapeutics: Website (external site)Investor relations (external site)SEC filings (external site)